Clinical trials: Eyes With Retinal Disease
Vitrectomy, Macular Pucker
Assessing the Efficacy and Safety fo DEXTENZA, Sustained Release Dexamethasone 0.4 mg Insert(s) for the Treatment of Pain, Inflammation, and Cystoid Macular Edema Following 27 Gauge Vitrectomy With Internal Limiting Membrane Peel for the Treatment of Retinal Edema Associated With Macular Pucker.
Assessing the efficacy and safety of DEXTENZA, sustained release dexamethasone 0.4 mg inserts following 27 gauge vitrectomy with internal limiting membrane peel
- Conditions
- Vitrectomy, Macular Pucker, Retinal Edema
- Trial name
- NCT04501367
- Testing
- Dexamethasone Intracanalicular Insert, 0.4 mg, Prednisone acetate 1%
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Kovach Eye Institute
Macular Edema, Central Retinal Vein Occlusion
Study to Assess the Safety and Tolerability of a Single Administration of FOV2302 (Ecallantide) in Patients With Macular Edema Associated With Central Retinal Vein Occlusion
The purpose of the study is to evaluate the safety and tolerability of a single administration of FOV2302 (ecallantide) in patients with macular edema associated with central retinal vein occlusion.
- Trial name
- FOV2302 (NCT00969293)
- Testing
- FOV2302 (Ecallantide)
- Where
- 8 sites in France
- Volunteers
- 11 people
- Sponsor
- Fovea Pharmaceuticals SA
Glaucoma Eye, Macular Degeneration
Retinal Oxygenation Estimation Trial With Mantis Photonics Hyperspectral Camera
An explorative study of the Mantis Photonics hyperspectral camera for retinal imaging and estimation of retinal oxygenation. Primary objective: To evaluate the performance of the hyperspectral camera for non-invasive retinal…
- Conditions
- Glaucoma Eye, Macular Degeneration, Macula Abnormality, Retinal Detachment
- Trial name
- NCT05566626
- Testing
- Hyperspectral retinal image, Mydriacyl Ophthalmic Product
- Where
- Sweden
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Mantis Photonics AB
Neovascular Age-Related Macular Degeneration (nAMD) Wet AMD
Ixoberogene Soroparvovec (Ixo-vec) Contralateral Dosing Study in Participants With Neovascular Age-related Macular Degeneration
The purpose of this study is to evaluate safety, effectiveness and durability of a gene therapy called Ixo-vec (Ixoberogene soroparvovec) when administered to the contralateral (second) eye of adult participants (≥ 50 years of…
- Trial name
- NCT07630649
- Testing
- Ixo-vec
- Where
- 12 sites in United States
- Volunteers
- 15 people
- Sponsor
- Adverum Biotechnologies, Inc.
Macular Edema
Safety, Tolerability and Efficacy of Intravitreal KIO-104 in Patients With Macular Edema
This is a multi-center, open label study to assess the safety, tolerability, and efficacy of KIO-104 administered by IVT injection to the study eye of eligible participants with macular edema.
- Trial name
- KLARITY-1 (NCT06825702)
- Testing
- KIO-104
- Where
- 6 sites in Australia
- Volunteers
- 28 people
- Sponsor
- Kiora Pharmaceuticals, Inc.
Neovascular Age-related Macular Degeneration
A Study to Assess the Efficacy and Safety of AKST4290 With Aflibercept in Patients With Newly Diagnosed nAMD
This study will evaluate the efficacy and safety of AKST4290 in combination with aflibercept injections in subjects with newly diagnosed neovascular age-related macular degeneration (nAMD).
- Trial name
- PHTHALO-205 (NCT04331730)
- Testing
- AKST4290, Aflibercept
- Where
- 21 sites in United States, Germany and 2 more
- Volunteers
- 107 people
- Sponsor
- Alkahest, Inc.
Age Related Macular Degeneration
A Study of the NeoVista Ophthalmic System for the Treatment of Subfoveal CNV Associated With Wet AMD in Patients That Require Persistent Anti-VEGF Therapy
The objective of the MERITAGE Trial is to evaluate the safety and efficacy of focal delivery of radiation for the treatment of subfoveal choroidal neovascularization (CNV) associated with wet age-related macular degeneration…
- Trial name
- MERITAGE (NCT00809419)
- Testing
- NeoVista Ophthalmic System
- Where
- 5 sites in United States, Israel and 1 more
- Volunteers
- 32 people
- Sponsor
- NeoVista
Age-Related Macular Degeneration
Safety and Tolerability of KH631 Gene Therapy in Participants With Neovascular Age-related Macular Degeneration
VAN-2201 is Phase I clinical trial to assess the safety and tolerability of KH631 in subjects with neovascular AMD. KH631 is gene therapy designed to deliver a protein which targets and blocks VEGF via an adeno-associated viral…
- Trial name
- NCT05657301
- Testing
- KH631
- Where
- 7 sites in United States
- Volunteers
- 25 people
- Sponsor
- Chengdu Origen Biotechnology Co., Ltd.
Age-related Macular Degeneration, Choroidal Neovascularization
Randomized Study for Efficacy and Safety of Ranibizumab 0.5mg in Treat-extend and Monthly Regimens in Patients With nAMD
This study was designed to evaluate the efficacy and safety of two different regimens of 0.5 mg ranibizumab given as intravitreal injection in patients with neovascular age-related macular degeneration
- Trial name
- TREND (NCT01948830)
- Testing
- Ranibizumab 0.5mg
- Where
- 91 sites in Belgium, Chile and 17 more
- Volunteers
- 650 people
- Sponsor
- Novartis Pharmaceuticals
Macular Edema
A Study to Evaluate an Updated Dexamethasone Intravitreal (Into the Eye) Applicator in Adult Participants With Macular Edema Due to Diseases of the Retina
The Dexamethasone Posterior Segment Drug Delivery System (DEX PS DDS) Applicator is used to deliver an implant with medicine to the eye. AbbVie is updating the DEX PS DDS Applicator.
- Trial name
- NCT04976777
- Testing
- Updated DEX PS DDS Applicator, Approved DEX PS DDS Applicator, Dexamethasone
- Where
- 7 sites in United States
- Volunteers
- 54 people
- Sponsor
- AbbVie
Macular Degeneration
Safety and Efficacy of Brimonidine Intravitreal Implant in Patients With Geographic Atrophy Due to Age-related Macular Degeneration (AMD)
Stage 1 is a patient-masked, dose-escalation, safety evaluation of brimonidine intravitreal implant. Patients will receive implant in one eye and "sham" treatment (meaning no treatment) in the fellow eye.
- Trial name
- NCT00658619
- Testing
- 400 µg Brimonidine Tartrate Implant, 200 µg Brimonidine Tartrate Implant
- Where
- 7 sites in United States, Australia and 5 more
- Volunteers
- 119 people
- Sponsor
- Allergan
Wet Age-related Macular Degeneration, Neovascular Age-related Macular Degeneration
A Study to Comparing SCD411 and Eylea® in Subjects With Wet Age-related Macular Degeneration (AMD)
Age-related macular degeneration (AMD) is a leading cause of vision loss in adults. Abnormal blood vessels grow under the macula at the back of the eye, and also leak blood and fluid, which damages and scars the macula, affecting…
- Trial name
- NCT04480463
- Testing
- SCD411, Aflibercept
- Where
- 130 sites in United States, Australia and 12 more
- Volunteers
- 576 people
- Sponsor
- Sam Chun Dang Pharm. Co. Ltd.
Macular Degeneration
Visudyne® in Occult (VIO)
The purpose of this study is to demonstrate that Visudyne therapy in patients who have occult with no classic subfoveal choroidal neovascularization (CNV) lesions will, with an acceptable safety profile, significantly reduce the…
- Trial name
- NCT00121407
- Testing
- Visudyne for injection
- Volunteers
- 364 people
- Sponsor
- QLT Inc.
Macular Degeneration
Vascular Endothelial Growth Factor VEGF Trap-Eye:Investigation of Efficacy and Safety in Wet Age-Related Macular Degeneration(AMD)
This study is a phase 3, double-masked, randomized, study of the efficacy and safety of VEGF Trap-Eye in patients with neovascular age-related macular degeneration.
- Trial name
- VIEW1 (NCT00509795)
- Testing
- ranibizumab, aflibercept injection (VEGF Trap-Eye, BAY86-5321)
- Where
- 188 sites in United States, Canada
- Volunteers
- 1,217 people
- Sponsor
- Regeneron Pharmaceuticals
Neovascular Age-Related Macular Degeneration
Safety and Pharmacokinetics of RTH258 in Subjects With Age-Related Macular Degeneration
The purpose of this study is to assess the systemic pharmacokinetics (PK) and safety of 2 different doses of brolucizumab (3 milligrams (mg)/50 microliters (μL) and 6 mg/50 μL) when administered at 4-week intervals for a total of…
- Trial name
- NCT02507388
- Testing
- Brolucizumab 3 mg/50 μL, Brolucizumab 6 mg/50 μL
- Volunteers
- 51 people
- Sponsor
- Alcon Research
Macular Degeneration
Evaluate the Effectiveness of Intravitreal (IVT) Aflibercept Injection in Clinical Practice in naïve Patients With Neovascular Age-related Macular Degeneration (nAMD)
There is a need to investigate the effectiveness of IVT aflibercept injection in routine clinical practice. The aim of this study is to collect 12-month real-world clinical data from treatment-naïve nAMD patients who started…
- Trial name
- REALE (NCT03411941)
- Testing
- Eylea (Aflibercept, VEGF Trap-Eye, BAY86-5321)
- Where
- Spain
- Volunteers
- 116 people
- Sponsor
- Bayer
Macular Edema, Retinal Vein Occlusion
Evaluation of OZURDEX® in Patients With Macular Edema Secondary to Retinal Vein Occlusion in China
This study will take place in China to evaluate the safety and efficacy of OZURDEX implant 700 μg in the treatment of macular edema due to retinal vein occlusion (RVO) in patients who have never received treatment for RVO.
- Trial name
- NCT03908307
- Testing
- OZURDEX
- Where
- 9 sites in China
- Volunteers
- 150 people
- Sponsor
- Allergan
Diabetic Macular Edema
Post Marketing Study to Evaluate the Safety and Effectiveness of Brolucizumab in Patients With Diabetic Macular Edema.
The purpose of this study is to generate additional safety and effectiveness data in Indian Diabetic macular edema (DME) patients that more closely resemble the real-world population intended to be treated with Brolucizumab.
- Trial name
- NCT05959304
- Testing
- brolucizumab
- Where
- 8 sites in India
- Volunteers
- 66 people
- Sponsor
- Novartis Pharmaceuticals
Macular Degeneration
Clinical Study Of Pegaptanib Sodium (EYE001) For Wet-Type Age-Related Macular Degeneration
This study will examine the safety and efficacy of pegaptanib sodium in Japanese patients with wet-type age-related macular degeneration (AMD), who benefit further treatment and who want to continue the treatment after completion…
- Trial name
- NCT00239928
- Testing
- pegaptanib sodium
- Where
- 12 sites in Japan
- Volunteers
- 61 people
- Sponsor
- Pfizer
Retinitis Pigmentosa
Intravitreal Injection of SeeQ CdSe 655 Alt Nanoparticles for Patients With Degenerative Retinal Diseases
This study was a prospective, open label feasibility study conducted at a single clinical site (APEC, Mexico City) to evaluate the safety and preliminary effectiveness of the SeeQ device, with each patient's serving as his/her…
- Trial name
- NCT04008771
- Testing
- SeeQ CdSe 655 ALT
- Where
- Mexico
- Volunteers
- 20 people
- Sponsor
- 2C Tech Corp